title: FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec.
abstract: 61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.
authors.affiliation: From the Departments of *Medical Imaging, †Dermatology, and ‡Oncology, University of Arizona College of Medicine, Banner University Medical Center Tucson; and §Departments of Medical Imaging, Medicine and Biomedical Engineering, University of Arizona College of Medicine, Tucson, AZ.
authors.forename: Matthew F
authors.initials: MF
authors.lastname: Covington
authors.forename: Clara N
authors.initials: CN
authors.lastname: Curiel
authors.forename: Lois
authors.initials: L
authors.lastname: Lattimore
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Avery
authors.forename: Phillip H
authors.initials: PH
authors.lastname: Kuo
mesh_terms: D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000628:therapy; D008875:Middle Aged; D050130:Oncolytic Virotherapy; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18